![Asceneuron Secures $100 Million Led by Novo for Alzheimer’s Drug Development](/content/images/size/w600/2024/07/e04d5949-5c33-4525-95a4-a606a40fc365.png)
Health
Asceneuron Secures $100 Million Led by Novo for Alzheimer’s Drug Development
Swiss biotech company Asceneuron has secured $100 million in a Series C funding round led by Novo Holdings, the investment arm of the Novo Nordisk Foundation. This funding will be used to advance the development of ASN51, an oral small-molecule inhibitor of O-GlcNAcase (OGA) aimed at treating Alzheimer's